Parameters affecting photodynamic activity of Foscan® or meta-tetra(hydroxyphenyl)chlorin (mTHPC) in vitro and in vivo

Lasers in Medical Science

Volumn 13, Issue 2, 1998, Pages 119-125

  Rezzoug, H ^a   Bezdetnaya, L ^a,c   A'amar, O ^a,b   Merlin, J L ^d   Guillemin, F ^a,b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^c Univ Médicale Russe   (France)

^d Centre Alexis Vautrin ^*

Author keywords

Human colon adenocarcinoma cells; Meta tetra(hydroxyphenyl)chlorin; Nude mice; Photodynamic therapy

Indexed keywords

EVANS BLUE; PHOTOSENSITIZING AGENT; PROTEIN; TEMOPORFIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG UPTAKE; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; INCUBATION TIME; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

EID: 0031819584     PISSN: 02688921     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101030050064     Document Type: Article

References (36)

1. Kessel D, Cheng ML Biologie and biophysical properties of the tumor-localizing components of hematoporphyrin derivative. Cancer Res 1985; 45:3053-8
2. Epe B. Genotoxicity of singlet oxygen. Chem Biol Interact 1991; 80:239-60
3. Weishaupt KR. Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photodestruction of a murine tumor. Cancer Res 1976; 36:2326-49
4. Bonnett R, White RD. Winfield UJ. Berenbaum MC. Hydroporphyrins of the meso-tetra (m-hydroxyphenyl) porphyrm series as tumour photosensitizers. Biochem J 1989; 1:277-80
5. Ash DV, Brown SB. News drugs and future developments in photodynamic therapy. Eur J Cancer 1993; 29:1781-3
6. Berenbaum MC, Bonnett R, Chevretton EB, Akande-Adebakin SL, Ruston M. Selectivity of mesotetra(hydroxyphenyl) porphyrins and chlorins and of Photofrin II in causing photodamage in tumour, skin, muscle and bladder; the concept of cost-benefit in analysing the results. Laser Med Sci 1993; 8:235-43
7. Ris HB. Altermati HJ, Nachbur B et al. Photodynamic therapy with meta-tetrahydroxyphenylchlorin in vivo: optimization of the therapeutic index. Int J Cancer 1993: 55:245-9
8. Ris HB, Altermati HJ. Nachbur B et al. Effect of drug-light interval on photodynamic therapy with m-Tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer 1993; 53 141-6
9. Dougherty TJ Review: photodynamic therapy. Photochem Photobiol 1993; 58:895 900
10. Fisher AMR. Linn Murphree A, Gomer CJ. Clinical and preclinical photodynamic therapy. Laser Surg Med 1995: 17:2-31
11. Peng Q, Moan J, Nesland JM. Correlation of subcellular and mtratumoral photosensitizer localisation with ultrastructural features after photodynamic therapy. Ultrastruct Pathol 1996; 20:109-29
12. Reed MWR, Mullins AP, Anderson GL, Miller FN, Wieman J. The effect of photodynamic therapy on tumor oxygenation. Surgery 1989; 106:94-9
13. Van Geel IPJ, Oppelaar H, Marijnissen JPA, Stewart FA. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. Radiat Res 1996; 145:602-9
14. Davila J, Harriman A. Photoreactions of macrocyclic dyes bound to human serum albumin. Photochem Photohiol 1990; 51:9-19
15. Michael Titus AT, Whelpton R, Yaqub Z. Binding of temoporphin to the lipoprotein fractions of human serum. Br J Clin Pharmacol 1995; 40:594-7
16. Tipping E, Ketterer B, Koskelo P. The binding of porphyrins by ligandin. Biochem J 1978: 164:509-16
17. Merlin JL, Azzi S, Lignon D, Ramacci C, Zeghari N. Guillemin F. MTT assays allow quick and reliable measurement of the response of human tumours cells to photodynamic therapy. Eur J Cancer 1992; 28:1452 8
18. Merlin JL, Azzi S, Guillemin F, Marchai C, Weber B. Photodynamic therapy: in vitro model with MCF-7 breast adenocarcinoma cells. Lasers Med Sci 1991; 6:120-1
19. McHale AP, McHale L. Use of a tetrazolium based colorimetric assay in assessing photoradiation therapy in vitro. Cancer Lett 1988; 41:315-21
20. Richter AM, Waterfield E, Jam AK et al. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol 1990; 52:495-500
21. Chou C, Talalay C. Quantitative analysis of dose effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55
22. Guillemin F, A'amar O, Rezzoug H et al Optical instrumentation suitable for real-time dosimetry during photodynamic therapy. SPIE 1996: 2627:92-9
23. 6. A morphologic study of tumor damage efficiency in experiment. J Photochem Photobiol B: Biol 1991; 11:307-18
24. Anholt H, Peng Q, Moan J. Pressure against the tumour can reduce the efficiency of photochemotherapy. Cancer Lett 1994; 82:73-80
25. Henderson BW, Waldow SM, Mang TS. Potter WR, Malone PB, Dougherty TJ. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 1985; 45:572-6
26. Vonarx-Coinsmann V, Foultier MT, Cempel N, Morlet L, Combrc A, Patrice T. In vitro and in vivo photodynamic effects of a new photosensitizer: tetra (m-hydroxyphenyl) chlorin. Laser Med Sci 1994; 9:173-81
27. Ris HB, Altermati HJ, Nachbur B et al. Intraoperative photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for chest malignancies. Laser Surg Med 1996; 44:39-45
28. Ma LW, Moan J, Berg K. Comparison of the photobleaching effect of three photosensitizing agents: Meso-tetra(m-hydroxyphenyl) chlorin, Meso-tetra(m-hydroxyphenyl)porphvrin and photofrin during photodynamic therapy. Laser Med Sci 1994; 9:127-32
29. Jori G. In vivo transport and pharmacokinetic behaviour of tumour photosensitizers. Ciba Foundation Symposium 146, Photosensitizing compounds: their chemistry, biology and clinical use. 1989: 78-94
30. Korbelik M, Hung J. Cellular delivery and retention of Photofrin II: the effects of interaction with human plasma proteins. Photochem Photobiol 1991, 53:501-10
31. Ben-Hur E, Siwecki JA, Newman HC, Crane SW, Rosenthal I. Mechanism of uptake of sulfonated metallophthalocyanines by cultured mammalian cells. Cancer Lett 1987; 38:215-22
32. Ma L, Moan J, Berg K. Evaluation of new photosensitizer, meso-tetra(hydroxyphenyl) chlorin, for use in photodynamic therapy a comparison of its photobiological properties with those of two other photosensitizers. Int J Cancer 1994; 57:883-8
33. Rezzoug H, Merlin JL, Zeghari N et al. Cellular uptake kinetics and photodynamic activity of mesotetrahydroxyphenylchlorin (mTHPC). SPIE 1995; 2625:386-94
34. Laukka MA, Wang KK. Bonner JA. Apoptosis occurs in lymphoma cells but not in hepatoma cells following ionizing radiation and photodynamic therapy. Dig Dis Sci 1994; 39:2467-75
35. Pe MB, Ikeda H, Inokuchi T. Tumor destruction and proliferation kinetics following periodic, low power light, haematoporphyrin oligomers mediated photodynamic therapy in the mouse tongue. Oral Oncol Eur J Cancer 1994; 3:174-8
36. Veenhuizen RB. Stewart FA. The importance of fluence rate in photodynamic therapy: is there a parallel with ionizing radiation dose-rate effects? Radiol Oncol 1995; 37:131-5